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Summary.-Prior splenectomy increased the resistance of BALB/c mice to a syn-
geneic methylcholanthrene-induced ascitic tumour inoculated i.p. The survival rate
of splenectomized mice was 81-60/ while those of normal and sham-operated controls
were 11.5%O and 20% respectively. The effect of splenectomy, however, was seen only
within the dose range of 103 to 104 tumour cells. This effect of splenectomy was
abolished by the transfer to mice of serum from tumour-bearing mice, and of spleen
cells from normal donors, immediately after the inoculation of tumour cells. Cell-
free ascitic fluid did not abolish the effect of splenectomy. The findings suggest that
there is a subpopulation of spleen cells which produces a tumour growth enhancing
factor which is found in the serum of tumour-bearing mice.
IN recent years, various investigators
have shown a renewed interest in the role
of the spleen in the immune response to
tumours, as the spleen is a relatively rare
site for metastases when compared to the
rest of the reticulo-endothelial system
(Willis, 1973). In vivo experiments to
examine the effect of splenectomy on the
behaviour of tumours used several differ-
ent criteria. Thus various workers have
examined the effect of splenectomy on (a)
the incidence of spontaneously arising
tumours (Whitmore, SalernoandRabstein,
1972; Check et al., 1974); (b) the induction
of tumours by chemical carcinogens
(Cohen, Headley and Bryan, 1973; Aka-
matsu, 1975); (c) the incidence of sponta-
neouis regression of tumours (Pollack,
1971; Ferrer and Mihich, 1968); and (d)
the behaviour of transplanted tumours
(Moller, 1965; Bansal and Sjogren, 1973,
1974). The results of these investigations
suggest that although splenectomy has no
effect on the incidence of spointaneous
tumours, or oni the induction of tumours
by chemical carcinogens, it reduces the
rate of growth of transplanted tumours,
and may increase the incidence of sponta-
neous regression of tumours. However,
several criticisms may be made of these
reports. The behaviour of transplanted
tumours has been followed by measure-
ment of the size of the tumour nodule, a
parameter whose significance is difficult
to interpret. Furthermore, the effect of
splenectomy on the survival of animals
with transplanted tumours has not been
reported, or has found to be negligible.
Using survival as the criterion, we
present evidence here that prior splenec-
tomy increases the host resistance to a
transplanted tumour. We have also
followed the behaviour ofthe transplanted
tumour, by determining the rate ofascites
formation and also bv tumour cell counts.
MATERIAL AND METHODS
Animals. Inbred BALB/c 1i1ce, 7-14
w%eeks old, obtained from the animal house of
the Institute of Basic Medical Sciences,
London, were used. They were kept in
plastic cages, 10 animals to each cage, and
given water and food pellets (FFG(M), DixonTUMOUR RESISTANCE OF SPLENECTOMIZED MICE
Diets for Scientific Research Animals) ad
libitum. Groups of 10 male mice were used
for all experiments unless otherwise stated.
Splenectomy.-Seven- to 12-week-old
BALB/c mice were anaesthetized with ether.
Under aseptic conditions, the spleen was
exposed through a left flank incision, the
vessels ligated and the organ removed. The
abdominal cavity was closed, usually with a
single suture through all layers, and dressed
with Savlon barrier cream (Imperial Chemical
Industries Ltd., Cheshire). Sham-operated
mice underwent the same procedure, except
thattheir spleens were notligated orremoved.
Operative deaths were usually the result ofan
overdose ofether, and when this was avoided
a mortality of less than 1% was achieved.
Splenectomy was performed 2 weeks before
tumour inoculation.
Tumour.-An ascitic form of a methyl-
cholanthrene-induced fibrosarcoma (MCA)
was used. It was originally obtained from the
Sloan-Kettering Institute for Cancer Re-
search, New York, and has been maintained
in the laboratory by serial passage in male
BALB/c every 2 weeks. The passage dose
was 5 X 104 tumour cells, suspended in
phosphate-buffered saline.
Tumour-cell suspensions.-The ascitic
tumour was obtained by tapping the abdo-
minal cavity of tumour-bearing animals.
The tumour cells were washed twice in ice-
cold phosphate-buffered saline (PBS) at
250 g for 10 min. No attempt was made to
remove the small number of contaminating
red blood cells. Viability determined by dye
exclusion (0-2% of trypan blue in PBS) in
the chamber of an improved Neubauer
haemocytometer was usually over 90%.
Cells were diluted to the required concentra-
tion with PBS and injected in 0 1-ml volumes.
The i.p. route was used in all experiments.
Spleen-cell suspensions.-Spleens removed
from mice killed by cervical dislocation were
crushed gently in ice-cold PBS with a glass
rod in glass centrifuge tubes. Tissue clumps
were allowed to settle and the cell suspension
removed. It was washed once with PBS and
centrifuged at 250 g for 10 min. Red cells
were lysed by hypotonic shock as follows: the
spleen cell pellet was resuspended in 1 ml of
PBS, about 4 ml of sterile water was added,
and the suspension stirred with a Pasteur
pipette for 5 s, when 6 ml ofPBS was added.
The suspension of spleen cells was then
washed for 5 min and resuspended in PBS.
Viability as determined by trypan blue
exclusion was usually more than 80%.
Mouse serum.-Mice were bled by division
of the thoracic part of the inferior vena cava
under ether anaesthesia, and the serum was
separated out by centrifugation after clotting.
Serum from tumour-bearing mice was ob-
tained from donors that had received 103
MCA tumour cells i.p. 2 weeks previously.
Cell-free ascitic fluid.-Ascitic fluid con-
taining tumour cells, obtained by tapping the
abdominal cavities oftumour-bearing animals
that had received 103 tumour cells i.p. 2
weeks previously, was spun twice at 500 g for
10 min. The supernatant fluid was removed,
and examined under the microscope to check
that it was free of cells.
Determination of survival rates and mean
time of death of tumour-bearing mice.-The
fate of all test and control animals was
followed for at least 50 days after tumour
inoculation: some mice were kept for more
than 270 days. The survival rate and mean
time of death were calculated. The data
presented here are usually the pooled results
of several experiments.
Rate offormation ofascites.-All mice were
individually marked and weighed on the first
day of the experiment, so that the change in
weight of each animal could be recorded.
The average weight of each group of animals
on various days was determined and ex-
pressed as a percentage ofthe average weight
of the group on Day 0. The animals were
usually weighed every 3 to 5 days, but more
often when ascites formation was rapid.
A preliminary experiment was performed
to check that the natural gain in weight ofthe
animals was of an order that would not
invalidate this method of estimation of the
rate offormation ofascites. The rate ofgain
in weight of 10 mice was recorded from the
day they were born until they were 22 weeks
old. The gain in weight reached a near-
plateau at about 7 weeks, after which the gain
in weight was 2% per week. Animals with
ascitic tumour gained about 3000 in weight
per week. The animals that succumbed to the
ascitic tumour usually died before showing
signs of malignant cachexia. The weight of
dead animals drained oftheir ascitic fluid was
usually within 2 g of their original weight.
Growth rate of tumour cells.-Normal and
splenectomized mice were injected i.p. with
103 tumour cells on Day 0. On various days
thereafter, 5 mice from each group were killed
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by cervical dislocation. The abdominal
cavity was opened and ascitic fluid collected
with a Pasteur pipette from those mice with
obvious ascites. The abdominal cavities of
all mice were washed out with 5 ml of PBS.
The final volumes of fluid collected was
measured, the number of tumour cells per
unit volume was determined on a haemo-
cytometer, and the total number of tumour
cells in the peritoneal cavity of each mouse
was calculated.
RESULTS
1. Survival of splenectomized mice given
different doses of tumour cells
The survival of splenectomized mice
given different doses of tumour cells was
compared with those ofnormal and sham-
operated mice (Fig. 1). There was no
difference between the survival rates of
the 3 groups whengivenmorethan 5 x 104
tumour cells, as all the animals died.
There was a slight increase in the survival
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rate ofthe splenectomized group given 104
cells: 23.8% compared with 6.7% for
normal and 10% for sham-operated mice
(P < 0.01).
There was a marked improvement in
the survival rate of splenectomized mice
that received 103 tumour cells, 81.6%
compared with 11.5% and 20% for normal
and sham-operated animals respectively.
This is highly significant, with P < 0 001
calculated by the x2 test.
A rather surprising finding was that
the survival rate for the splenectomized
group was not much better than that for
normal and sham-operated animals given
102 tumour cells (0.1 < P < 0 2).
The mean time of death (MTD) of the
3 groups ofanimals was compared (Fig. 2).
There was no difference between the
MTDs of the animals that died from the
tumour in all 3 groups.
2. Rate offormation of ascites
The rate of formation of ascites for
each of the 3 groups was determined for
mice given 103 tumour cells (Fig. 3).
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FiG. 1.-Survival ofsplenectomized mice (A)
compared with normal (EO) and sham-
operated controls (-).
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FIG. 2.-Mean time ofdeathofsplenectomized
mice (-) compared with that of normal
(O) and sham-operated controls (-).
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Fia. 3.-Rate offormation of ascites by nor-
mal (D), sham-operated (-) and splenec-
tomized mice (-) inoculated i.p. with 103
MCA tumour cells. Each curve represents
the mean weight of 10 animals. The mean
weight of each group at Day 0 is expressed
as 100.
There was a rapid increase in the weight
and, presumably, the amount of ascites
formed, in normal and sham-operated
mice from Day 12. These animals began
to die when their weight reached more
than 130% of their original weight.
Splenectomized mice, however, gained
relatively little in weight.
3. Growth rate of ascites tumour cells
The growth of MCA tumour cells
within the peritoneal cavity ofnormal and
splenectomized mice inoculated with 103
tumour cells is shown in Fig. 4. Each
point in the curves represents the mean
number of tumour cells recovered from 5
animals. In normal mice, the number of
tumour cells increased rapidly from 103
cells to 106 cells in the first 4 days,
indicating a doubling time of 91 h. The
number of cells continued to increase
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FIG. 4.-Growth of MCA tumour cells in
splenectomized (A) and normal mice (Eli)
given 103 tumour cells. Each point is the
mean of 5 animals.
thereafter, but at a much slower rate.
The doubling time for the second phase
was about 38 h, which is 4 x slower than
the first phase. The animals began to die
from Day 16, when the number of
tumour cells reached more than 108.
The tumour cells multiplied at the
same rate in splenectomized as in normal
animals until Day 4, after which the
number of tumour cells recovered de-
creased, until none were found after
Day 20. About 10-30% of splenecto-
mized animals succumbed to the MCA
tumour. Those animals with obvious
external signs of ascites after Day 15 were
excluded from the tumour-cell count,
since the point of the experiment was to
follow the behaviour of tumour cells in
animals protected by prior splenectomy.
The results suggest that splenectomy
protected BALB/c mice from a dose of
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103 tumour cells, a dose which killed over
8000 of normal mice. The protective
effect was apparently associated with an
event manifesting itself about 4 days after
tumour inoculation. Those animals that
died did so at about the same time as
normal or sham-operated animals.
4. The effect of transferring spleen cells to
splenectomized mtice
Since splenectomyprotected micegiven
103 MCA tumour cells i.p., the possibility
that the effect would be reversed by the
injection of spleen cells was considered.
So 108 spleen cells from normal syngeneic
mice (one spleen equivalent) were injected
i.p. into a group of mice immediately after
103 tumour cells had been given by the
same route. A similar experiment was
done with 108 spleen cells taken from mice
that had received 5 x 104 tumour cells
10 days previously.
Spleen cells from both normal and
tumour-bearing donors reversed the pro-
tective effect ofprior splenectomy (Fig. 5).
Those animals, however, that received
spleen cells from tumour-bearing animals
died earlier (MTD - 12-5 days) than
animals given the same number of normal
spleen cells (MTD 18.2 days). The
presence of metastatic tumour cells in the
spleens from tumour-bearing donors, in-
creasing the effective tumour dose, was
considered to be a likely explanation for
this observation. This was confirmed by
another experiment, in which it was found
that normal mice developed the ascitic
tumour 12 days after receiving 108 spleen
cells from tumour-bearing donors.
5. The effect of transferring serum from
tumour-bearing mice
The presence in serum from tumour-
bearing mice of blocking factors which
enhance the growth of tumour has been
reported by many workers (Hellstrom,
Hellstrom and Sjogren, 1970; Sjogrenetal.,
1971). So the possibility that the effect of
splenectomy may be reversed by the
transfer of serum from tumour-bearing
mice was tested. Serum obtained from
tumour-bearing mice was diluted 1/2 and
used immediately; 0 1-ml volumes were
given i.p. to splenectomized mice that had
just received 103 tumour cells by the same
route.
One control group of mice received
0 1-ml volumes of normal serum similarly
diluted 1/2. A second group of splenecto-
mized animals received tumour cells alone.
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FiG. 5.- The effect of transfer of 108 spleen cells to splenectomized mice given 103 tumour cells on the
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bearing animals; N = normal mice. At least 10 animals in each group.
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FIc. 6. Effect of transferring serum or ascitic fluid on the suirvival of splenectomized mice
injected with 103 tumouir cells. 10 animals in each group.
Since it was possible that ascitic fluid
from tumour-bearing animals might also
contain blocking factors, a fourth group of
splenectomized animals was given cell-free
ascitic fluid in addition to tumnour cells.
Serum from tumour-bearing mice re-
versed the protective effect ofsplenectomy
(Fig. 6). Normal serum and cell-free
ascitic fluid had no effect.
DISCUSSION
The most striking finding of this study
is that splenectomized BALB/c mice were
protected from death caused by the
growth of a methylcholanthrene-induced
ascitic tumour inoculated i.p. The degree
of protection was marked: 81U6o of
splenectomized mice survived a tumour
dose that killed 88 5% of normal and 80%
of sham-operated controls, a 4-fold im-
provement in the survival rate. While
these results show increased resistance as
a short-term effect of splenectomy, pre-
liminary experiments indicate that this
effect may be seen up to 5 months after
splenectomy.
The protective effect of splenectomy
was abolished by the transfer of normal
spleen cells. Further it was found that,
while 108 normal spleen cells (1 spleen
equivalent) were able to abolish the pro-
tective effect of splenectomy, 106 and 107
normal spleen cells did this only partially
and 105 normal spleen cells had no effect.
Previous reports used the size of
tumour nodule to monitor the effect of
splenectomy, and the ultimate survival of
the animals was not noted. This study
shows a protective effect of splenectomy
using survival as the criterion. With this
criterion, it was possible to obtain a more
clear-cut end point-the animals either
died or lived. Further, there was good
correlation with the rate of ascites forma-
tion and the tumour cell counts. When
tumour nodule size is measured, it is
never clear what is being measured, as
there may be necrotic areas present and
also cellular infiltrate. This study there-
fore provides unequivocal evidence of
increased resistance to transplanted
tumours in splenectomized mice.
The finding that normal spleen cells
abolished the protective effect of splenec-
tomy indicates that the anatomical inte-
grity of the spleen is not a prerequisite for
the sensitization of the cells that are
responsible for the enhancement oftumour
growth. This is not surprising, since it is
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well known that incubation of spleen cells
with tumour cells in vitro results in their
becoming sensitized to tumour antigens.
The protective effect of splenectomy
was seen only within a fairly narrow range
oftumour cell dose: 103 to 104 cells. This
suggests that within this dose range, the
host-tumourrelationship isfinelybalanced
and that it may be tipped in favour ofthe
host if the tumour-growth-enhancing cells
are removed by splenectomy.
A possible implication of the present
observation is that incidental splenectomy
during the surgical resection of carcinoma
of the stomach or colon may affect the
long term prognosis in these patients. It
would be of interest to conduct a survey
to see if this is the case.
The model described in this investiga-
tion demonstrated a protective effect of
splenectomy performed before the estab-
lishment of the tumour, a procedure
which could not be used therapeutically.
Therefore one ofthe most obvious lines for
future investigation would be to see if
splenectomy performed after the intro-
duction of a tumour can protect the host.
A second observation concerning the
dose-dependent effect of splenectomy was
that there was little difference among the
survival rates of splenectomized, normal
and sham-operated mice given 102 tumour
cells. Norlund and Gershon (1975) re-
ported a similar finding. They trans-
planted a syngeneic murine melanoma
(Cloudman S91) to DBA/2 mice, and
found that tumours appeared earlier in
splenectomized animals than in normal
animals when a small tumour inoculum
(104 cells) was used. The converse
happened with a larger tumour inoculum
(106 cells). They suggested that the
immunosuppressive effect of the spleen
with larger amounts of antigen was due to
the stimulation of suppressor T cells.
They offered no explanation for the
immunopotentiating role of the spleen
with smaller amounts ofantigen. Perhaps
splenic suppressor T cells or enhancing
antibody-producing cells are not stimu-
lated by a small antigenic load.
Tumour cells in both normal and
splenectomized mice divided rapidly dur-
ing the first 4 days after tumour inocula-
tion, cell doubling time being about 91 h.
After Day 4, although the rate of division
of the tumour cells in normal animals was
reduced, they continued to multiply until
the animals died with 108 to 109 tumour
cells in their peritoneal cavities from Day
16 onwards, butinsplenectomizedanimals,
the number of tumour cells began to fall
about Day 4 and continued to disappear
until Day 18, when the animals were free
of tumour cells.
The following hypothesis is proposed
to explain this phenomenon, and repre-
sented diagrammatically in Fig. 7. It is
suggested that the slope of the line AB
represents the rate of division of tumour
cells in both normal and splenectomized
animals before an immune response has
been established, a rate that would have
continued along BE if there was no
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FIG. 7. Diagrammatic representation of
tumour cell kinetics in normal and splenec-
tomized animals. For explanation see
Discussion.
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response. The slope of the line BC
represents the net rate ofkilling oftumour
cells in splenectomized hosts by sensitized
killer cells, unhampered by suppressor
cells or blocking factors that had pre-
viously been removed by splenectomy.
BD represents the net growth rate of
tumour cells, which allows for both the
killing oftumour cells by effector cells and
the greater enhancement oftumourgrowth
by either splenic suppressor cells and/or
blocking factors which inhibit the effector
cells.
Serum from tumour-bearing animals
abolished the protective effect of splenec-
tomy. Biddle (1976) has recently reported
similar findings using BI x C3H mice and
a syngeneic methylcholanthrene-induced
tumour. He showed that serum from
tumour-bearing mice, when mixed with
specific tumour cells before inoculation
into syngeneic recipients that had been
crippled immunologically by adult thy-
mectomy and whole-body irradiation, was
able to enhance the growth oftransplanted
tumour, as measured by the size of the
subcutaneous nodule 6 weeks later. This
enhancing effect was absorbed by incuba-
tion with specific tumour cells.
There have been many reports docu-
menting the presence of blocking factors
in sera from tumour-bearing animals.
Hellstrom et al. (1970) reported that
serum from tumour-bearing BALB/c mice
inhibited the cellular response of lymph-
node cells to a syngeneic methylchol-
anthrene-inducedtumour, asdemonstrated
by the colony inhibition assay. They also
found that there was less blocking activity
in serum obtained from tumour-bearing
mice that had been splenectomized.
Sjogren et al. (1971) provided evidence
that suggested that the blocking factors
wereantigen-antibody complexes. Bowen,
Robins and Baldwin (1975) also demon-
strated the presence of blocking antigen-
antibody complexes in serum obtained
from rats bearing the rat hepatoma D23.
The inability of cell-free ascitic fluid to
reverse the protective effect of splenec-
tomy was unexpected, as it was thought to
.5.1
be a likely source of blockinig factors.
However, it is possible that since ascitic
fluid bathes millions of tumour cells in the
peritoneal cavity of the tumour-bearing
mice, the blocking factors will have
adsorbed to the surface of those cells.
The adsorption of serum blocking factors
by incubation with specific tumour cells
has recently been reported (Biddle, 1976).
Our findings therefore suggests that
there is a subpopulation of spleen cells
which produces a tumour-growth-enhanc-
ing factor that is found in the serum of
tumour-bearing mice. The characteriza-
tion ofthe cell population involved will be
the subject of a further communication.
In addition it is planned to characterize
the serum factor, particularly with respect
to its specificity and chemical relation to
immunoglobulin.
This work was supported by a Fellow-
ship from the Bernard Sunley Charitable
Foundation and also by funds from the
Cancer Research Campaign. The authors
would also like to thank Dr Nina Wedder-
burn for her criticisms and suggestions.
REFERENCES
AKAMATSU, Y. (1975) Neoplasma in Strains of
Splenectomized Mice after a Single 7,12-Di-
methylbenz(a)anthracene Treatment. J. natn.
Cancer Inst., 55, 893.
BANSAL, S. C. & SJOGREN, H. 0. (1973) Correlation
between Changes in Antitumour Immune Para-
meters and Tumour Growth In vivo in Rats. Fed.
Proc., 32, 165.
BANSAL, S. C. & SJOGREN, H. 0. (1974) Anti-tumour
Immune Response and its Manipulation in a
Tumour-bearing Host. Israel J. med. Sci. 10, 939.
BIDDLE, C. (1976) Stimulation of Transplanted 3-
Methyleholanthrene-induced Sarcomas in Mice by
Specific Immune and Normal Serum. Int. J.
Cancer, 17, 755.
BOWEN, J. G., ROBINS, R. A. & BALDWIN, R. W.
(1975) Serum Factor Modifying Cell Mediated
Immunity to Rat Hepatoma D23 Correlated with
Tumour Growth. Int. J. Cancer, 15, 640.
CHECK, J. H., BRADY, L. W., LEIPOLD, P. L. &;
O'NEILL, E. A. (1974) Protection against Trans_
planted and Spontaneous Lymphoma by Inocu-
lation of Heat-altered Syngeneic Tumor Cells in
Splenectomized Mice. Cancer, N.Y., 34, 197.
COHEN, S. M., HEADLEY, D. B. & BRYAN, G. T.
(1973) The Effect of Adult Thymectomy and
Adult Splenectomy on the Production of Leu-
kaemia and Stomach Neoplasms in Mice by
NN-(4-(5-Nitro-2-furyl)-2-thiazolylacetamide. Can-
cer Res., 33, 637.776 R. W. S. CHANG AND J. L. TURK
FERRER, J. F. & MIHICH, E. (1968) Effect ofSplenec-
tomy on the Regression of Transplantable
Tumours. Cancer Res., 28, 1116.
HELLSTROM, I., HELLSTROM, K. E. & SJOGREN,
H. 0. (1970) Serum mediated Inhibition of
Cellular Immunity to Methylcholanthrene-induced
Murine Sarcomas. Cell. Immunol. 1, 18.
MOLLER, E. (1965) Interaction between Tumor and
Host during Progressive Neoplastic Growth in
Histoincompatible Recipients. J. natn. Cancer
In8t.,35, 1053.
NORLUND, J. J. & GERSHON, R. K. (1975) Splenic
Regulation of the Clinical Appearance of Small
Tumours. J. Immunol., 114, 1486.
POLLACK, S. B. (1971) Effect of Host Sex and
Splenectomy on Molony Virus-induced Sarcomas.
Int. J. Cancer, 8, 264.
SJOGREN, H. O., HELLSTROM, I., BANSAL, S. C. &
HELLSTROM, K. E. (1971) Suggestive Evidence
that " blocking Antibodies " of Tumor-bearing
Individuals may be antigen-antibody Complexes.
Proc. natn. Acad Sci. U.S.A. 68, 1372.
WHITMORE, C. E., SALERNO, R. A. & RABSTEIN,
L. A. (1972) Effects ofThymectomy, Splenectomy
and 3-Methylcholanthrene on Neoplasia Expres-
sion, Incidence and Latency in AKR Mice. Proc.
Soc. exp. Biol. Med., 141, 890.
WILLIS, R. A. (1973) The Spread of Tumour in the
Human Body. 3rd Ed. London: Butterworths.